LY03004
Sponsors
Luye Pharma Group Ltd.
Conditions
Schizoaffective DisorderSchizophrenia
Phase 1
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
CompletedNCT02055287
Start: 2013-03-31End: 2014-06-30Updated: 2014-11-10
Bioavailability of LY03004 and Risperdal® Consta®
CompletedNCT02091388
Start: 2014-09-30End: 2015-01-31Updated: 2015-03-04
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
CompletedNCT02186769
Start: 2014-07-31End: 2015-04-30Updated: 2015-06-18